Mavyret is a fixed dose combination of the direct-acting antiviral agents, glecaprevir, a HCV NS3/4A protease inhibitor, and pibrentasvir, an HCV NS5A inhibitor.

The Chicago hospitals will serve as "Elite Special Pathogen Treatment Centers" with the $1.5 million from IDPH.

As winter settles over Australia, it's not just the drop in temperature we notice—there's also a sharp rise in respiratory ...

The global respiratory syncytial virus respiratory syncytial virus treatment market is undergoing rapid growth, driven by rising vaccine uptake, impr ...

RSV is responsible for around 1 lakh deaths, over 3.6 million hospitalisations in children under age of 5 every year, ...

The respiratory virus, which primarily affects the respiratory ... Currently, no specific antiviral treatment or vaccine exists for HMPV. The management of HMPV infections focuses on supportive ...

RSV Infection: Understanding the differences between HMPV and RSV is crucial for timely diagnosis, prevention, and management. As their immune systems are still developing, infants are more ...

However, Dr. Sainalabdeen explained that HMPV is a common virus, which was first identified in 2001 in ... Dr. George further added that most patients recover well with basic symptom management at ...

HMPV Case LIVE: The HMPV virus was first identified in 2001 ... department will review the preparedness for surveillance and management and deliberate on the steps to be taken to address the ...